Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brenetafusp + tebentafusp
- Development stage
- Unknown
- Lead developer
- Immunocore
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
**Brenetafusp + tebentafusp** is a combination of two ImmTAC (immune mobilizing monoclonal TCRs against cancer) bispecific biologic drugs, both developed by Immunocore. Brenetafusp targets PRAME (preferentially expressed antigen in melanoma) and engages CD3 on T cells, while tebentafusp targets gp100 and also engages CD3. Both agents redirect cytotoxic T cells to tumor cells expressing their respective antigens through HLA-A*02:01 presentation. Tebentafusp is approved for unresectable or metastatic uveal melanoma and demonstrates overall survival benefit, while brenetafusp is in phase 1 studies primarily for ovarian cancer. Both drugs, when combined or with other agents, are under investigation for synergistic efficacy in enhancing antitumor immune responses in solid tumors resistant to other immunotherapies[3][4][1][2].
- Brand names
- Kimmtrak (tebentafusp)
- Other names
- brenetafusptebentafusp
02
Targets
CD3 (T-cell surface glycoprotein CD3)PMEL (Melanocyte Protein PMEL)PRAME peptide–HLA complex
Beyond the preview
Go deeper on brenetafusp + tebentafusp.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brenetafusp + tebentafusp.